<DOC>
	<DOCNO>NCT01517724</DOCNO>
	<brief_summary>The aim trial determine whether bortezomib improves response delay progression multiple myeloma patient high dose therapy autologous stem cell transplant . It also assess effect bortezomib treatment patient bone health .</brief_summary>
	<brief_title>Bortezomib Consolidation Trial</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>MM patient receive high dose Melphalan ASCT 34 month prior registration progress Age 18 70 year Life expectancy &gt; 6 month Written inform consent Creatinine &lt; 400µmol/L Bilirubin &lt; 3x upper limit normal WHO performance status 02 Contraceptive precaution appropriate Received bortezomib previously On , plan , steroid therapy Poor performance status ( ECOG ≥ 3 ) Disease progression stage Past history polio , cord compression neurological condition result persist neurological deficit ≥ grade 2 Severe hepatic impairment , indicate bilirubin ≥ 3x upper limit normal , AST &gt; 2.5x upper limit normal Pregnant lactate woman Allergic reaction attributable bortezomib compound contain boron mannitol Severe cardiovascular disease History acute infiltrative pulmonary pericardial disease History hypotension decrease blood pressure Peripheral neuropathy ≥ grade 2 , neuropathic pain Serious medical psychiatric illness likely interfere participation clinical study Received drug agent inhibit induce CYP2C19 CYP3A4 within 14 day first dose bortezomib Need therapy concomitant CYP 3A4 CYP2C19 inhibitor Have receive experimental drug use experimental medical device within 4 week plan start treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>MM</keyword>
	<keyword>HDT</keyword>
	<keyword>ASCT</keyword>
	<keyword>consolidation</keyword>
	<keyword>bortezomib</keyword>
</DOC>